SUCAMPO PHARMACEU-A (NASDAQ:SCMP)
3.71
0.08 (2.11%)
| SUCAMPO PHARMACEU-A (NASDAQ:SCMP) Delayed : | |||||
|---|---|---|---|---|---|
| Previous Close | $3.79 | 52 Week High | $8.78 | ||
| Open | $3.80 | 52 Week Low | $2.74 | ||
| Day High | $3.90 | P/E | N/A | ||
| Day Low | $3.62 | EPS | $-0.13 | ||
| Volume | 70,617 | ||||
| More SCMP Info: Chart SEC Filings Profile Historical Options | |||||
What is this?Friends, Peers and Foes
| Ticker | # Stories | Ticker | # Stories |
|---|---|---|---|
| QSFT | 2 | SEPR | 1 |
| ARTNA | 1 | CFN | 1 |
| EBS | 1 | GOK | 1 |
| INAP | 1 | LGN | 1 |
| MWIV | 1 | PDC | 1 |
| RSCR | 1 | STN | 1 |
Entities who have mentioned SCMP
- Bankruptcy | View Related Stories »
- UBS | View Related Stories »
- Citi | View Related Stories »
- Standard & Poor's | View Related Stories »
- Life, Style and Real Estate | View Related Stories »
- Credit Suisse | View Related Stories »
- After-Hours Movers | View Related Stories »
- Carl Icahn | View Related Stories »
- Initial Jobless Claims | View Related Stories »
- GLG Partners | View Related Stories »
- Trading Radar | View Related Stories »
View All Major News StreetInsider.com Major News for SCMP
- Sucampo Pharma (SCMP) Posts Q3 Break Even EPS; Misses by 3c
- Sucampo Pharmaceuticals (SCMP) Reports Q2 In-Line
- Sucampo Pharma (SCMP) Reports Q4 Loss of $0.07, Misses by 1c
View All ReportsStreetInsider.com Reports on SCMP
- Sucampo Pharma (SCMP) Subsidiary Granted Marketing Authorization for Amitiza in Switzerland
- Sucampo Pharma (SCMP) Posts Q3 Break Even EPS; Misses by 3c
- Trading Radar for 11/05: Starbucks (SBUX), CBS Corp. (CBS), CVS (CVS), Toyota (TM), Thomson Reuters (TRI)
- Sucampo Pharmaceuticals (SCMP) Appoints James J. Egan as COO
- Sucampo (SCMP) Withdraws European Marketing Authorization Application for Lubiprostone
View All Press ReleasesCompany Press Releases on SCMP
- Sucampo Receives Marketing Authorization for Amitiza(R) in Switzerland for Treatment of Chronic Idiopathic Constipation
- Sucampo Pharmaceuticals Invites Investors to Listen to Webcast of Presentation at Credit Suisse Conference
- Sucampo Pharmaceuticals Reports Financial Results for the Third Quarter of 2009
- Sucampo to Release Third Quarter 2009 Financial Results and Conduct a Conference Call on November 5, 2009
- Sucampo Appoints William L. Ashton to Board of Directors
StreetInsider Reports on SCMP by Category
View All BlogsBlogs on SCMP
- Progenics: Investors Are Right To Be Wary
- Surviving Wednesday's Wild Ride in Healthcare and Biotech
- Sucampo Pharmaceuticals, Inc. Q1 2009 Earnings Call Transcript
- Biopharma: Instead of M&A, Think P&A
- Sucampo Pharmaceuticals, Inc. Q4 2008 Earnings Call Transcript
View All FilingsSEC Filings on SCMP
- Form 10-Q Sucampo Pharmaceuticals, For: Sep 30
- Form 8-K Sucampo Pharmaceuticals, For: Nov 05
- Form 8-K Sucampo Pharmaceuticals, For: Oct 15
- Form 4 Sucampo Pharmaceuticals, For: Oct 15 Filed by: Ashton William
- Form 4 Sucampo Pharmaceuticals, For: Oct 07 Filed by: MAUDLIN TIMOTHY I
Comments on SCMP
No comments are currently available.
